Treatment status,a CXR, and TB class by IGRA result | n (% of all participants) | Incident active TB cases, n (% cases in sub-group) | Total follow-up (person-years) | Incidence rate per 100,000 person-years (95Â % CI) |
---|---|---|---|---|
All participants | 1152 (100) | 7 (0.60) | 7730 | 91 (43–190) |
 IGRA- | 639 (55) | 2 (0.31) | 4139 | 48 (12–193) |
 IGRA+ | 513 (45) | 5 (0.97) | 3591 | 139 (58–335) |
Inadequate or no TB treatment | 498 (43) | 4 (0.80) | 3148 | 127 (48–339) |
 IGRA- | 433 (38) | 2 (0.46) | 2698 | 74 (19–296) |
 IGRA+ | 65 (6.0) | 2 (3.1) | 451 | 443 (111–1775) |
Adequate TB treatment | 654 (57) | 3 (0.46) | 4581 | 65 (21–203) |
 IGRA- | 206 (18) | 0 | 1441 | 0 |
 IGRA+ | 448 (39) | 3 (0.67) | 3140 | 96 (31–296) |
Normal CXRb | 269 (23) | 1 (0.37) | 1553 | 64 (9.1–457) |
 IGRA- | 216 (19) | 0 | 1206 | 0 |
 IGRA+ | 53 (4.6) | 1 (1.9) | 347 | 288 (41–2047) |
Abnormal CXR | 881 (77) | 6 (0.68) | 6158 | 97 (44–217) |
 IGRA- | 421 (37) | 2 (0.48) | 2914 | 69 (17–274) |
 IGRA+ | 460 (40) | 4 (0.87) | 3244 | 123 (46–329) |
B1 TB, Pulmonary | 561 (49) | 5 (0.89) | 3630 | 138 (57–331) |
 IGRA- | 276 (24) | 1 (0.36) | 1759 | 57 (8.0–404) |
 IGRA+ | 285 (25) | 4 (1.4) | 1870 | 214 (80–570) |
B2 (LTBI) | 588 (51) | 2 (0.34) | 4084 | 49 (12–196) |
 IGRA- | 361 (31) | 1 (0.28) | 2370 | 42 (5.9–300) |
 IGRA+ | 227 (20) | 1 (0.44) | 1714 | 58 (8.2–414) |
B3 (Contacts) | 3 (0.26) | 0 | 16 | 0 |